Trial Profile
A Multicenter, Single Arm, Open-label Trial of Oxaliplatin Plus Capecitabine (XELOX) in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2020
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Gastric cancer; Intestinal cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms NEO-CLASSIC Study
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2018 Status changed to active, no longer recruiting as per results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 23 Dec 2015 Planned primary completion date changed to 1 May 2016.